Liver transplantation (LT) is a high-risk, high-cost intervention that extends life in more than 7,000 patients in the United States each year. However, cardiovascular disease (CVD) negatively affects outcomes among LT recipients. Since 2002, CVD mortality after LT has increased by 50% (Fig. 1), and CVD is now the leading cause of early (<1 year) and the third leading cause of late (>1 year) mortality.1-4 Approximately 30% of liver transplant recipients will have a CVD complication (myocardial infarction, heart failure, cardiac arrest, atrial fibrillation, pulmonary embolism, or stroke) within 1 year of LT.
2-4CVD outcomes after LT are influenced by LT-specific and traditional CVD risk factors. Current liver allocation policy in the United States is based on Model for EndStage Liver Disease (MELD) score (range 6-40). The MELD system is intended to allow the greatest access to transplant for the sickest patients, and thus organs are prioritized toward patients with the highest scores. As a result, such patients have a high burden of critical illness. 5 Critically ill patients have an increased prevalence of subclinical and clinical CVD. 4 In addition, over the past decade there has been a marked rise in the prevalence AQ1 AQ2